WAYNE, PA-Shire Pharmaceuticals has dropped its plan to build a new headquarters in Malvern, and will remain here at the Chesterbrook Corporate Center.
A report in the Philadelphia Business Journal referred to a “dramatic” and “stunning” decision that was not formally announced, but was passed along to companies working on the new headquarters plan this week.
Shire, which employs about 1,500, announced last October that it would relocate to Atwater. It had considered moving its North American headquarters to New Jersey or Delaware, but opted to stay in the Philadelphia region, the company said at the time.
Shire had planned to move out of 425,000 square feet at Chesterbrook by the end of 2015. Construction plans were for ten buildings with 1.15 million square feet at Atwater, where Endo Pharmaceuticles broke ground in January for its new $65 million headquarters.
“We're no longer moving forward with that and we're remaining in Chesterbrook,” a spokeswoman for Shire told the Business Journal Thursday. Read more here.
Shire's home base is Dublin, Ireland.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
